CDK5 and neoplasm: Tumor volume in Dinaciclib-treated mice was significantly inhibited compared with placebo and untreated groups, indicating that loss of CDK5 could inhibit the tumorigenesis of NSCLC (Fig. 4d, e) (P < 0.05).